Researchers have uncovered the mechanism underlying frontotemporal lobar degeneration (FTLD) caused by variants in the ...

Dementia is an incurable disease, but it is possible to delay its onset and progress with early detection. The symptoms can ...

But the real story is in Acadia's R&D pipeline, which looks ready to explode ... expected by 2026 and a new Phase 2 study for Lewy Body Dementia starting later this year. These aren't just ...

Acadia is playing for keeps. It's not just about crushing 2025 sales recordsit's about building a powerhouse. With a strong lineup of innovative therapies, a clear path to European revenues, and some ...

A new study led by Western researchers found frequent treatment with intranasal oxytocin – a hormone in the brain associated ...

A new study from Karolinska Institutet and Mayo Clinic has revealed important insights into brain degeneration in dementia with Lewy bodies (DLB). This research, published in JAMA Neurology, could ...

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced multiple business updates and progress on the Company's CNS and rare disease drug candidates, which will be discussed today during a ...

2024 was an exciting year for ProMIS as we transitioned from an R&D company into a clinical-stage company with ... Parkinson's disease and Lewy Body Dementia and PMN311 a potential vaccine against AD.

Sleep disturbances are common in old age, but drastic changes, such as waking up at 3 am or not being able to stay awake ...

AURORA, Colo. (Jan. 10, 2025) – Cognitive profiles for early diagnosis of Dementia with Lewy bodies (DLB) have been outlined in a new study, out today in Alzheimer’s & Dementia. Although DLB ...

C2N Diagnostics LLC, a St. Louis-based biotechnology firm that developed blood-based tests for Alzheimer's and other neurological diseases, has received a grant from The Michael J. Fox Foundation for ...